Efficacy and safety of CHF6001, a novel inhaled PDE4 inhibitor in COPD: the PIONEER study

BACKGROUND: This study evaluated the efficacy, safety and tolerability of the novel inhaled phosphodiesterase-4 inhibitor CHF6001 added-on to formoterol in patients with chronic obstructive pulmonary disease (COPD). METHODS: Randomised, double-blind, placebo- and active-controlled, parallel-group st...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Respir Res
Egile Nagusiak: Singh, Dave, Emirova, Aida, Francisco, Catherine, Santoro, Debora, Govoni, Mirco, Nandeuil, Marie Anna
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2020
Gaiak:
Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7510119/
https://ncbi.nlm.nih.gov/pubmed/32962709
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12931-020-01512-y
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak